{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:11:27Z","timestamp":1787886687291,"version":"build-2784847793"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["CP18\/00111"],"award-info":[{"award-number":["CP18\/00111"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"publisher","award":["CP18\/00146"],"award-info":[{"award-number":["CP18\/00146"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"publisher","award":["PI018\/00606\\u2033"],"award-info":[{"award-number":["PI018\/00606\\u2033"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"publisher","award":["CM19\/00251"],"award-info":[{"award-number":["CM19\/00251"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012371","name":"Faculty of Science and Engineering, University of Manchester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012371","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jinf.2022.06.005","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T11:13:13Z","timestamp":1654945993000},"page":"322-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["High efficacy of glecaprevir\/pibrentasvir for HCV-infected individuals with active drug use"],"prefix":"10.1016","volume":"85","author":[{"given":"Alejandro","family":"Gonzalez-Serna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Corma-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Tellez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Cucurull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7429","authenticated-orcid":false,"given":"Luis M","family":"Real","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5813-6889","authenticated-orcid":false,"given":"Antonio","family":"Rivero-Juarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Hernandez-Quero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Collado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan A.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2022.06.005_bib0001","unstructured":"WHO (World Health Organization). Combating hepatitis B and C to reach elimination by 2030. Available at: https:\/\/www.whoint\/hepatitis\/publications\/hep-elimination-by-2030-brief\/en\/2016. Last access: 232\/6\/2022."},{"key":"10.1016\/j.jinf.2022.06.005_bib0002","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/hiv.13039","article-title":"Incidence of recently acquired hepatitis C virus infection among HIV-infected patients in southern Spain","volume":"22","author":"Gonzalez-Serna","year":"2021","journal-title":"HIV Med"},{"key":"10.1016\/j.jinf.2022.06.005_bib0003","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jinf.2022.06.005_bib0004","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","article-title":"The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study","volume":"4","author":"Trickey","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jinf.2022.06.005_bib0005","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/liv.14043","article-title":"Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting","volume":"39","author":"Socias","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jinf.2022.06.005_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2019.02.018","article-title":"Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy","volume":"71","author":"Mac\u00edas","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jinf.2022.06.005_bib0007","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2022.06.005_bib0008","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2022.06.005_bib0009","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.29541","article-title":"Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: a partially randomized phase 3 clinical trial","volume":"67","author":"Wyles","year":"2018","journal-title":"Hepatololgy"},{"key":"10.1016\/j.jinf.2022.06.005_bib0010","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2022.06.005_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208506","article-title":"Safety and efficacy of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older","volume":"14","author":"Foster","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jinf.2022.06.005_bib0012","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugpo.2019.01.011","article-title":"Safety and efficacy of glecaprevir\/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy","volume":"66","author":"Grebely","year":"2019","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.jinf.2022.06.005_bib0013","series-title":"Outcomes of patients interrupting glecaprevir\/pibrentasvir treatment: a case series from clinical trials","author":"Zamor","year":"2019"},{"key":"10.1016\/j.jinf.2022.06.005_bib0014","first-page":"125","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic HCV infection","volume":"9","author":"Liu","year":"2021","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jinf.2022.06.005_bib0015","unstructured":"Gu\u00edas AEEH\/SEIMC de manejo de la Hepatitis C. 2018; Available at: https:\/\/seimc.org\/contenidos\/gruposdeestudio\/gehep\/dcientificos\/documentos\/gehep-seimc_AEEH-dc-2018-HepatitisC.pdf. Last access: 23\/06\/2022"},{"key":"10.1016\/j.jinf.2022.06.005_bib0016","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1111\/liv.14152","article-title":"Staying hepatitis C negative: a systematic review and meta-analysis of cure and reinfection in people who inject drugs","volume":"39","author":"Latham","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jinf.2022.06.005_bib0017","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugpo.2019.01.011","article-title":"Safety and efficacy of glecaprevir\/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy","volume":"66","author":"Grebely","year":"2019","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.jinf.2022.06.005_bib0018","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrgastro.2017.106","article-title":"Direct-acting antiviral agents for HCV infection affecting people who inject drugs","volume":"14","author":"Grebely","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jinf.2022.06.005_bib0019","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/cid\/ciw806","article-title":"From care to cure: demonstrating a model of clinical patient navigation for hepatitis C care and treatment in high-need patients","volume":"64","author":"Ford","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2022.06.005_bib0020","series-title":"Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV\/HCV coinfected persons who inject drugs","author":"Ward","year":"2017"},{"key":"10.1016\/j.jinf.2022.06.005_bib0021","first-page":"125","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic HCV infection","volume":"9","author":"Liu","year":"2021","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jinf.2022.06.005_bib0022","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jinf.2022.06.005_bib0023","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jhep.2016.07.042","article-title":"Global genotype distribution of hepatitis C viral infection among people who inject drugs","volume":"65","author":"Robaeys","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jinf.2022.06.005_bib0024","unstructured":"European Commission Grants AbbVie Marketing Authorization Shortening MAVIRET\u00ae (glecaprevir\/pibrentasvir) Treatment Duration to Eight Weeks for Treatment-Na\u00efve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis. AbbVie Press Release 2020. Available from: https:\/\/news.abbvie.com\/news\/press-releases\/european-commission-grants-abbvie-marketing-authorization-shortening-maviret-glecaprevirpibrentasvir-treatment-duration-to-eight-weeks-for-treatment-nave-chronic-hcv-patients-with-genotype-3-and-compensated-cirrhosis.htm?view_id=4284. Accessed October 2021."},{"key":"10.1016\/j.jinf.2022.06.005_bib0025","unstructured":"Mavyret (glecaprevir and pibrentasvir) US full prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209394s008lbl.pdf. [Accessed October 2021]."},{"key":"10.1016\/j.jinf.2022.06.005_bib0026","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jinf.2022.06.005_bib0027","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1007\/s12325-021-01753-3","article-title":"Safety of patients with hepatitis C virus treated with glecaprevir\/pibrentasvir from clinical trials and real-world cohorts","volume":"38","author":"Forns","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.jinf.2022.06.005_bib0028","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","article-title":"The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study","volume":"4","author":"Trickey","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jinf.2022.06.005_bib0029","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","article-title":"The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study","volume":"4","author":"Trickey","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445322003589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445322003589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:00:27Z","timestamp":1777492827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445322003589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0163445322003589"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2022.06.005","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High efficacy of glecaprevir\/pibrentasvir for HCV-infected individuals with active drug use","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2022.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}